Vir Biotechnology, Inc. · NASDAQ:VIR
Vir Biotechnology — Goldman Sachs 45th Annual Global Healthcare Conference 2024
5 slides from Vir Biotechnology's conference presentation, Jun 12, 2024
Slide 1: Goldman Sachs 45th Annual Global Healthcare Conference
Goldman Sachs 45th Annual Global Healthcare Conference June 12, 2024 Confidential © 2024 Vir Biotechnology, Inc.™
Slide 2: Legal Disclaimer
Legal Disclaimer Forward-Looking Statements Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding the near-term financial performance of Vir Biotechnology, Inc. (the
Slide 3: Sustained HDV RNA Virologic Suppression Observed for Tobevibart + Elebsiran Combination Rollover
Sustained HDV RNA Virologic Suppression Observed for Tobevibart + Elebsiran Combination Rollover Following Monotherapy Lead-in Durable Anti-HDV Activity SOLSTICE TRIAL: rollover tobevibart + elebsiran combination therapy 1 Monotherapy (from day 0) Combination therapy (from day 113) Rollover cohort:
Slide 4: De Novo Tobevibart + Elebsiran: Rapid Virologic Response and High Rates of HDV RNA Suppression
De Novo Tobevibart + Elebsiran: Rapid Virologic Response and High Rates of HDV RNA Virologic Suppression and ALT Normalization Rapid Virologic Response Demonstrated ALT normalization Week 12 Week 24 De novo tobevibart + elebsiran combination therapy De novo tobevibart + elebsiran combination therapy
Slide 5: Tobevibart Monotherapy: High Rates of HDV RNA Virologic Suppression and ALT Normalization
Tobevibart Monotherapy: High Rates of HDV RNA Virologic Suppression and ALT Normalization High Rate of Virologic Response1 Demonstrated ALT normalization Week 12 Week 24 tobevibart monotherapy tobevibart monotherapy n=264 n=114 8 Virologic 19/26 6/11 tobevibart 90 tobevibart Response2 (73%) (55%) 7
Vir Biotechnology — Goldman Sachs 45th Annual Global Healthcare Conference 2024 on 6ix